spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  QLT  

 HSMN NewsFeed - 5 Jan 2021
DURECT Corporation Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 21 Jun 2018
Alimera Sciences Appoints Mary T. Szela to its Board of Directors
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 9 Apr 2017
Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 27 Aug 2015
InSite Vision and QLT Amend Merger Agreement
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 24 Oct 2014
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 9 Oct 2014
Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Aug 2014
Auxilium Pharmaceuticals, Inc. Appoints Andrew Saik Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2012
QLT Announces Reduction in Force
Biopharmaceuticals
 HSMN NewsFeed - 24 Sep 2012
QLT Announces Sale of Visudyne(R) to Valeant Pharmaceuticals
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Jun 2012
Sucampo Appoints Dipak Panigrahi, MS, MD, as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2012
QLT Announces the Appointment of Christopher Muller as Chief Commercial Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 19 Mar 2012
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 20 Dec 2010
NovaDigm Therapeutics Appoints C. Boyd Clarke to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2010
Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2010
QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne(R)) Combination Therapy in Exudative AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Apr 2010
QLT Names Dipak Panigrahi, M.D., as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 22 Feb 2010
QLT Names Joseph L. Turner to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Dec 2009
QLT Acquires Early-Stage Ophthalmic Asset for US$7.5 Million
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 7 Dec 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Nov 2009
QLT announces MGH litigation settlement
Biopharmaceuticals Licensing Litigation Ophthalmology
 HSMN NewsFeed - 19 Oct 2009
QLT restructures Visudyne(R) agreement
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Sep 2008
Tekmira Pharmaceuticals Expands Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2008
Transcend Medical Announces New President and CEO and Appointment of Chairman of the Board
Devices Ophthalmology Personnel
 HSMN NewsFeed - 26 Aug 2008
QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 28 Mar 2008
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Mar 2008
QLT announces positive FDA action on Aczone(TM)
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2008
QLT reduces workforce as first step in its strategic restructure
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Cannasat Therapeutics Appoints Dr. Julia Levy to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2007
QLT Completes Acquisition of ForSight Newco II, Inc.
Biopharmaceuticals Ophthalmology Drug Delivery
 HSMN NewsFeed - 9 Oct 2007
ForSight Labs Announces Acquisition of ForSight Newco II by QLT, Inc.
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 9 Oct 2007
QLT acquires leading edge ocular drug delivery system from ForSight Labs
Biopharmaceuticals Ophthalmology Drug Delivery
 HSMN NewsFeed - 31 Aug 2007
Eligard(R) six-month formulation successfully completes European approval procedure
Biopharmaceuticals Drug Delivery Regulatory Oncology
 HSMN NewsFeed - 23 Jul 2007
QLT announces FDA filing and review of Aczone(TM) labeling supplement for removal of blood screening requirement
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 29 May 2007
QLT USA, Inc. files Aczone(TM) labeling supplement for removal of blood screening requirement
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 1 May 2007
QLT strengthens its expertise in ocular by adding David A. Saperstein M.D. as interim Chief Medical Officer and Paul L. Kaufman M.D. as Head of the Ocular Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2007
QLT announces that CHMP will recommend to the European Commission that occult indication be deleted from the Visudyne(R)label in European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 23 Apr 2007
CollaGenex Pharmaceuticals Provides Update on Examination of Incyclinide Patent Application
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Mar 2007
Protox Announces Senior Management Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Mar 2007
QLT Settles MEEI Lawsuit With Respect to the '303 Patent
Biopharmaceuticals Ophthalmology Litigation
 HSMN NewsFeed - 20 Dec 2006
CollaGenex Pharmaceuticals Signs License and Supply Agreement with MediGene for Marketing Rights to Oracea in EU and Certain Other Countries
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 1 Dec 2006
Eligard(R) six-month formulation approved in Germany
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Nov 2006
Intradigm Announces Significant Enhancements of the Company Capabilities, a New Series A Financing and Important Addition to Senior Management Team
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 30 May 2006
CollaGenex Pharmaceuticals Receives FDA Approval for Oracea(TM)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 25 May 2006
QLT strengthens corporate development and legal functions with the appointment of Peter J. O'Callaghan as Senior Vice President, Corporate Development and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2006
AnorMED President and CEO Michael Abrams steps down
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 52

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 52 additional stories matching:
QLT
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.